These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 15128945)

  • 1. Translocation and cleavage of myocardial dystrophin as a common pathway to advanced heart failure: a scheme for the progression of cardiac dysfunction.
    Toyo-Oka T; Kawada T; Nakata J; Xie H; Urabe M; Masui F; Ebisawa T; Tezuka A; Iwasawa K; Nakajima T; Uehara Y; Kumagai H; Kostin S; Schaper J; Nakazawa M; Ozawa K
    Proc Natl Acad Sci U S A; 2004 May; 101(19):7381-5. PubMed ID: 15128945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A new paradigm for the progression of advanced heart failure].
    Kawada T; Nakazawa M; Toyo-oka T
    Nihon Yakurigaku Zasshi; 2004 Feb; 123(2):55-62. PubMed ID: 14745124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel paradigm for therapeutic basis of advanced heart failure--assessment by gene therapy.
    Kawada T; Masui F; Kumagai H; Koshimizu M; Nakazawa M; Toyo-Oka T
    Pharmacol Ther; 2005 Jul; 107(1):31-43. PubMed ID: 15963350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel scheme of dystrophin disruption for the progression of advanced heart failure.
    Kawada T; Masui F; Tezuka A; Ebisawa T; Kumagai H; Nakazawa M; Toyo-Oka T
    Biochim Biophys Acta; 2005 Aug; 1751(1):73-81. PubMed ID: 16054019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy prevents disruption of dystrophin-related proteins in a model of hereditary dilated cardiomyopathy in hamsters.
    Toyo-oka T; Kawada T; Xi H; Nakazawa M; Masui F; Hemmi C; Nakata J; Tezuka A; Iwasawa K; Urabe M; Monahan J; Ozawa K
    Heart Lung Circ; 2002; 11(3):174-81. PubMed ID: 16352094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decrease in sarcoglycans and dystrophin in failing heart following acute myocardial infarction.
    Yoshida H; Takahashi M; Koshimizu M; Tanonaka K; Oikawa R; Toyo-oka T; Takeo S
    Cardiovasc Res; 2003 Aug; 59(2):419-27. PubMed ID: 12909325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarcolemmal fragility secondary to the degradation of dystrophin in dilated cardiomyopathy, as estimated by electron microscopy.
    Kawada T; Hemmi C; Fukuda S; Tezuka A; Iwasawa K; Nakazawa M; Sato H; Toyo-Oka T
    Exp Clin Cardiol; 2003; 8(2):67-70. PubMed ID: 19641652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissociation of sarcoglycans and the dystrophin carboxyl terminus from the sarcolemma in enteroviral cardiomyopathy.
    Lee GH; Badorff C; Knowlton KU
    Circ Res; 2000 Sep; 87(6):489-95. PubMed ID: 10988241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rescue of hereditary form of dilated cardiomyopathy by rAAV-mediated somatic gene therapy: amelioration of morphological findings, sarcolemmal permeability, cardiac performances, and the prognosis of TO-2 hamsters.
    Kawada T; Nakazawa M; Nakauchi S; Yamazaki K; Shimamoto R; Urabe M; Nakata J; Hemmi C; Masui F; Nakajima T; Suzuki J; Monahan J; Sato H; Masaki T; Ozawa K; Toyo-Oka T
    Proc Natl Acad Sci U S A; 2002 Jan; 99(2):901-6. PubMed ID: 11805334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Somatic gene therapy of dilated cardiomyopathy].
    Kawada T; Nakazawa M; Toyo-Oka T
    Nihon Yakurigaku Zasshi; 2002 Jan; 119(1):37-44. PubMed ID: 11862755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calpain-mediated dystrophin disruption may be a potential structural culprit behind chronic doxorubicin-induced cardiomyopathy.
    Campos EC; O'Connell JL; Malvestio LM; Romano MM; Ramos SG; Celes MR; Prado CM; Simões MV; Rossi MA
    Eur J Pharmacol; 2011 Nov; 670(2-3):541-53. PubMed ID: 21946105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dystrophin disruption in enterovirus-induced myocarditis and dilated cardiomyopathy: from bench to bedside.
    Badorff C; Knowlton KU
    Med Microbiol Immunol; 2004 May; 193(2-3):121-6. PubMed ID: 12920582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered membrane proteins and permeability correlate with cardiac dysfunction in cardiomyopathic hamsters.
    Ikeda Y; Martone M; Gu Y; Hoshijima M; Thor A; Oh SS; Peterson KL; Ross J
    Am J Physiol Heart Circ Physiol; 2000 Apr; 278(4):H1362-70. PubMed ID: 10749734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dystrophin deficiency in Drosophila reduces lifespan and causes a dilated cardiomyopathy phenotype.
    Taghli-Lamallem O; Akasaka T; Hogg G; Nudel U; Yaffe D; Chamberlain JS; Ocorr K; Bodmer R
    Aging Cell; 2008 Mar; 7(2):237-49. PubMed ID: 18221418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remodeling of dystrophin and sarcomeric Z-band occurs in pediatric cardiomyopathies: a unifying mechanism for force transmission defect.
    Vatta M; Sinagra G; Brunelli L; Faulkner G
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):149-56. PubMed ID: 19194174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe dystrophic cardiomyopathy caused by the enteroviral protease 2A-mediated C-terminal dystrophin cleavage fragment.
    Barnabei MS; Sjaastad FV; Townsend D; Bedada FB; Metzger JM
    Sci Transl Med; 2015 Jul; 7(294):294ra106. PubMed ID: 26136477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy.
    Badorff C; Lee GH; Lamphear BJ; Martone ME; Campbell KP; Rhoads RE; Knowlton KU
    Nat Med; 1999 Mar; 5(3):320-6. PubMed ID: 10086389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The expression of dystrophin in human viral myocarditis and dilated cardiomyopathy].
    Xu HF; Li YH; Chen Y; Cheng LB
    Fa Yi Xue Za Zhi; 2006 Feb; 22(1):12-4. PubMed ID: 16524176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uniform low-level dystrophin expression in the heart partially preserved cardiac function in an aged mouse model of Duchenne cardiomyopathy.
    Wasala NB; Yue Y; Vance J; Duan D
    J Mol Cell Cardiol; 2017 Jan; 102():45-52. PubMed ID: 27908661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory cardiomyopathy: there is a specific matrix destruction in the course of the disease.
    Towbin JA
    Ernst Schering Res Found Workshop; 2006; (55):219-50. PubMed ID: 16329665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.